by Reitsamer R, Peintinger F, Forsthuber E, Sir A
The Breast VOLUME 57, P113-117, JUNE
01, 2021 (Published: March 25, 2021)
Background
Targeted axillary dissection (TAD), the combination of
sentinel lymph node biopsy (SLNB) and targeted lymph node biopsy (TLNB), can
reduce the false negative rates of sentinel node biopsy alone dramatically in
breast cancer patients, who received neoadjuvant chemotherapy (NAC). However
methods for TAD are still under investigation.
Methods
Magseed®, a non-radioactive magnetic marker was used to mark
the biopsied positive TLN after NAC. The SLNB with the standard
technetium-based method and the selective TLNB with Magseed® localization were
performed in 40 patients. The TLNs were identified with the Sentimag® probe and
excised in all patients. Specimen x-ray was performed to confirm the Magseed®
within the prior to NAC biopsied and clipped lymph node.
Results
The TLN identification rate was 100% (40/40), the SLN
identification rate was 82.5% (33/40), the concordance rate between the TLN and
the SLN was 65% (26/40). Complications according Magseed® deployment or
identification could not be observed.
Conclusion
Magseed® is a reliable and feasible marker for the
identification of TLNs after NAC.
